๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Regulation of B Cell Function by Bucillamine, a Novel Disease-Modifying Antirheumatic Drug

โœ Scribed by Shunsei Hirohata; Peter E. Lipsky

Book ID
118768579
Publisher
Elsevier Science
Year
1993
Tongue
English
Weight
578 KB
Volume
66
Category
Article
ISSN
1090-2341

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Regulation of B Cell Function by Lobenza
Regulation of B Cell Function by Lobenzarit, A Novel Disease-Modifying Antirheumatic Drug
โœ Shunsei Hirohata; Satoshi Shinohara; Tetsufumi Inoue; Terumasa Miyamoto; Peter E ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 718 KB

Objective. Lobenzarit (disodium 4-chloro-2,2'iminodibenzoate [CCA]) is a novel disease-modifying drug for the treatment of rheumatoid arthritis (RA). Although its clinical efficacy has been demonstrated, its mechanism of action remains unclear. We therefore examined the effects of CCA on in vitro Ig

Inhibition of mitogen-induced response o
Inhibition of mitogen-induced response of human peripheral blood mononuclear cells by bucillamine, a new antirheumatic sulfhydryl drug
โœ T. Akamatsu; T. Matsubara; Y. Saegusa; K. Mizuno ๐Ÿ“‚ Article ๐Ÿ“… 1994 ๐Ÿ› Springer ๐ŸŒ English โš– 516 KB

The mechanism of action of bucillamine, [N-(2-mercapto-2-methylpropionyl)-L-cysteine] (BC), a novel antirheumatic drug that is used in patients with rheumatoid arthritis (RA), was compared with that of D-penicillamine (DP). BC inhibited phytohemagglutinin (PHA)-induced DNA synthesis of peripheral bl